From professional translators, enterprises, web pages and freely available translation repositories.
non-inferiority margin
granica neinferiornosti
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the non-inferiority margin was 15 %.
granica neinferiornosti bila je 15%.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
statistical non-inferiority was not achieved.
nije postignuta statistička neinferiornost.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
non-inferiority p-value (hr)
p-vrijednost za superiornost
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
immunologic non-inferiority to 7-valent prevenar
neinferiornost imunološkog odgovora naspram 7-valentnog cjepiva prevenar
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
ap<0.0001 for assessment of non-inferiority to prn
ap<0,0001 za procjenu neinferiornosti prema režimu p.p.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
conclusions supported non-inferiority regardless of analysis method.
zaključci su potvrdili neinferiornost neovisno o metodi analize.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
§ the paediatric population was not sized to test for non-inferiority.
§ pedijatrijska populacija nije bila prikladne veličine za ispitivanje neinferiornosti.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
this study failed to demonstrate non-inferiority of rotigotine to ropinirole.
ispitivanje nije uspjelo dokazati neinferiornost rotigotina u odnosu na ropinirol.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the prespecified non-inferiority margin for the treatment difference was 20%.
prethodno postavljena granica neinferiornosti za razliku između terapija bila je 20%.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
table 7 key efficacy results for the non-inferiority analysis of study no16966
tablica 7 ključni rezultati djelotvornosti iz analize o neinferiornosti u ispitivanju no16966
Last Update: 2017-04-26
Usage Frequency: 3
Quality:
similar efficacy for rilpivirine was seen in each trial demonstrating non-inferiority to efavirenz.
u oba se ispitivanja opazila slična djelotvornost rilpivirina čime se pokazala njegova neinferiornost u odnosu na efavirenz.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
efficacy was based on demonstrating non-inferiority of intravenous palonosetron compared to intravenous ondansetron.
djelotvornost se temeljila na dokazivanju neinferiornosti intravenski primijenjenog palonosetrona u usporedbi s intravenskim ondansetronom.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
0.89 (0.70, 1.13) p-value < 0.0001 (non-inferiority)
0,89 (0,70, 1,13) p-vrijednost < 0,0001 (neinferiornost)
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
Warning: Contains invisible HTML formatting
confidence interval entirely below non-inferiority margin of 1.154 n number of patients randomised.
interval pouzdanosti je u cijelosti ispod granice neinferiornosti od 1,154 n broj randomiziranih bolesnika.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
pregabalin did not achieve non-inferiority to lamotrigine based on the 6-month seizure freedom endpoint.
pregabalin nije pokazao neinferiornost u odnosu na lamotrigin s obzirom na mjeru ishoda: postizanje 6-mjesečnog razdoblja bez napadaja.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the efficacy analyses using pq population are consistent with the analyses for the itt population and support the non-inferiority of ac versus gc.
analize djelotvornosti na pq populaciji konzistentne su s analizama itt populacije i podupiru neinferiornost kombinacije ac naspram gc.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
f) a confidence interval lying entirely above -10% indicates a non-inferiority of eylea to ranibizumab
f) interval pouzdanosti koji je potpuno iznad -10% pokazuje da eylea nije inferiorna ranibizumabu
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
the objective of the part 2 was to establish the non-inferiority in observed ctrough levels between the confirmed mabthera subcutaneous dose and the reference mabthera intravenous dose.
cilj 2. dijela ispitivanja bio je utvrditi neinferiornost opaženih vrijednosti ctrough kod primjene potvrđene doze supkutane formulacije lijeka mabthera i referentne doze intravenske formulacije lijeka mabthera.
Last Update: 2017-04-26
Usage Frequency: 1
Quality:
#demonstration of non-inferiority required that the lower bound of the 95% ci of the gmt ratio be greater than 0.67.
#dokaz neinferiornosti zahtijevao je da niža granica 95% ci-a omjera gmt-a bude viša od 0,67.
Last Update: 2017-04-26
Usage Frequency: 1
Quality: